Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer |
Lim, Dansaem
(Division of Biological Sciences, Sookmyung Women's University)
Do, Yeojin (Division of Biological Sciences, Sookmyung Women's University) Kwon, Byung Su (Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital) Chang, Woochul (Department of Biology Education, College of Education, Pusan National University) Lee, Myeong-Sok (Division of Biological Sciences, Sookmyung Women's University) Kim, Jongmin (Division of Biological Sciences, Sookmyung Women's University) Cho, Jin Gu (Division of Biological Sciences, Sookmyung Women's University) |
1 | Sestito R, Cianfrocca R, Rosano L et al (2016) Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sci 159, 43-48 DOI |
2 | Orecchia P, Balza E, Pietra G et al (2019) L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. Cancers (Basel) 11, 1232-1250 DOI |
3 | Kim J (2018) MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology. BMB Rep 51, 65-72 DOI |
4 | Hernandez R, Sanchez-Jimenez E, Melguizo C, Prados J and Rama AR (2018) Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives. BMB Rep 51, 563-571 DOI |
5 | Suh N (2018) MicroRNA controls of cellular senescence. BMB Rep 51, 493-499 DOI |
6 | Kinose Y, Sawada K, Nakamura K and Kimura T (2014) The role of microRNAs in ovarian cancer. Biomed Res Int 2014, 249393 DOI |
7 | Sun Q, Zou X, Zhang T, Shen J, Yin Y and Xiang J (2014) The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. Gynecol Oncol 132, 730-738 DOI |
8 | Salinas-Vera YM, Gallardo-Rincon D, Garcia-Vazquez R et al (2019) HypoxamiRs Profiling Identify miR-745 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells. Front Oncol 9, 381 DOI |
9 | Cao L, Wan Q, Li F and Tang CE (2018) MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep 51, 456-461 DOI |
10 | Choi PW and Ng SW (2017) The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition. Int J Mol Sci 18, 1207-1226 DOI |
11 | Shibuya M (2008) Vascular endothelial growth factordependent and -independent regulation of angiogenesis. BMB Rep 41, 278-286 DOI |
12 | Monk BJ, Minion LE and Coleman RL (2016) Antiangiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27 Suppl 1, i33-i39 DOI |
13 | Siegel RL, Miller KD and Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69, 7-34 DOI |
14 | Sudo T (2012) Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol 17, 424-429 DOI |
15 | Hennessy BT, Coleman RL and Markman M (2009) Ovarian cancer. Lancet 374, 1371-1382 DOI |
16 | Webb PM and Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41, 3-14 DOI |
17 | Park JA and Kwon YG (2018) Hippo-YAP/TAZ signaling in angiogenesis. BMB Rep 51, 157-162 DOI |
18 | Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18 DOI |
19 | Ribatti D, Annese T, Ruggieri S, Tamma R and Crivellato E (2019) Limitations of Anti-Angiogenic Treatment of Tumors. Transl Oncol 12, 981-986 DOI |
20 | Dunleavey JM and Dudley AC (2012) Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy. Curr Angiogenes 1, 133-138 DOI |
21 | Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155, 739-752 DOI |
22 | Zhang X, Zhang J, Zhou H, Fan G and Li Q (2019) Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry. J Cancer 10, 6327-6340 DOI |
23 | Chae YC and Kim JH (2018) Cancer stem cell metabolism: target for cancer therapy. BMB Rep 51, 319-326 DOI |
24 | Sood AK, Fletcher MS, Zahn CM et al (2002) The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1, 661-664 DOI |
25 | Park Y and Kim J (2019) Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells. BMB Rep 52, 214-219 DOI |
26 | Fan YL, Zheng M, Tang YL and Liang XH (2013) A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett 6, 1174-1180 DOI |
27 | Yu L, Zhu B, Wu S et al (2017) Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagn Pathol 12, 23 DOI |
28 | Liang J, Yang B, Cao Q and Wu X (2016) Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer. Gynecol Obstet Invest 81, 529-536 DOI |
29 | Zhang D, Sun B, Zhao X et al (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13, 207 DOI |
30 | Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu GL (2012) Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res 31, 16 DOI |
31 | Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936 DOI |
32 | Boocock CA, Charnock-Jones DS, Sharkey AM et al (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87, 506-516 DOI |
33 | Markowska A, Sajdak S, Markowska J and Huczynski A (2017) Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. Eur J Med Chem 142, 87-94 DOI |
34 | Chen Y, Zhang L, Liu WX and Wang K (2018) VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett 23, 2 DOI |
35 | Wang JY, Sun T, Zhao XL et al (2008) Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther 7, 758-766 DOI |
36 | Reinthaller A (2016) Antiangiogenic therapies in ovarian cancer. Memo 9, 139-143 DOI |
37 | Richardson DL (2019) New and Novel Therapies for Gynecologic Cancers. Semin Oncol Nurs 35, 217-219 DOI |
38 | Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81, 17-38 DOI |
39 | Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65, 4389-4400 DOI |
40 | Ledermann JA, Embleton AC, Raja F et al (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 387, 1066-1074 DOI |
41 | Raja FA, Griffin CL, Qian W et al (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 105, 884-889 DOI |
42 | Pick AM and Nystrom KK (2012) Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther 34, 511-520 DOI |
43 | Yu K, Xiang L, Li S, Wang S, Chen C and Mu H (2019) HIF1alpha promotes prostate cancer progression by increasing ATG5 expression. Anim Cells Syst (Seoul) 23, 326-334 DOI |
44 | Schoffski P (2012) Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 12, 711-723 DOI |
45 | Cong R, Sun Q, Yang L, Gu H, Zeng Y and Wang B (2009) Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 28, 124 DOI |
46 | Cheng N, Brantley DM, Liu H et al (2002) Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1, 2-11 DOI |
47 | Manandhar S and Lee YM (2018) Emerging role of RUNX3 in the regulation of tumor microenvironment. BMB Rep 51, 174-181 DOI |
48 | Zimna A and Kurpisz M (2015) Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed Res Int 2015, 549412 DOI |
49 | Zhang S, Zhang D and Sun B (2007) Vasculogenic mimicry: current status and future prospects. Cancer Lett 254, 157-164 DOI |
50 | Sun B, Zhang D, Zhang S, Zhang W, Guo H and Zhao X (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249, 188-197 DOI |
51 | Su M, Feng YJ, Yao LQ et al (2008) Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer 18, 476-486 DOI |
52 | Herr F, Baal N, Reisinger K et al (2007) HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 28 Suppl A, S85-93 DOI |
53 | du Bois A, Kristensen G, Ray-Coquard I et al (2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 17, 78-89 DOI |
54 | Pignata S, Lorusso D, Scambia G et al (2015) Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 16, 561-568 DOI |
55 | du Bois A, Floquet A, Kim JW et al (2014) Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32, 3374-3382 DOI |
56 | Floquet A, Vergote I, Colombo N et al (2015) Progressionfree survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol 136, 37-42 DOI |
57 | Muller CY and Cole LA (2009) The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol 112, 663-672 DOI |
58 | Su M, Wei W, Xu X et al (2011) Role of hCG in vasculogenic mimicry in OVCAR-3 ovarian cancer cell line. Int J Gynecol Cancer 21, 1366-1374 DOI |
59 | Awasthi N and Schwarz RE (2015) Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther 8, 3691-3701 DOI |
60 | Hughes G, Toellner H, Morris H, Leonard C and Chaudhuri N (2016) Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med 5, 78-89 DOI |
61 | Monk BJ, Poveda A, Vergote I et al (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15, 799-808 DOI |
62 | van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL and Griffioen AW (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev 67, 441-461 DOI |
63 | Sood AK, Seftor EA, Fletcher MS et al (2001) Molecular determinants of ovarian cancer plasticity. Am J Pathol 158, 1279-1288 DOI |
64 | Vartanian AA, Burova OS, Stepanova EV and Baryshnikov AY (2007) The involvement of apoptosis in melanoma vasculogenic mimicry. Melanoma Res 17, 1-8 DOI |
65 | Gao S, Fan C, Huang H, Zhu C, Su M and Zhang Y (2016) Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo. Oncol Lett 12, 459-466 DOI |
66 | Qiao L, Gu Q, Dai Y et al (2008) XIAP-associated factor 1 (XAF1) suppresses angiogenesis in mouse endothelial cells. Tumour Biol 29, 122-129 DOI |
67 | Zhu LM, Shi DM, Dai Q et al (2014) Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget 5, 5403-5415 DOI |
68 | Wang Y, Liu P, Wang X and Mao H (2017) Role of Xlinked inhibitor of apoptosisassociated factor1 in vasculogenic mimicry in ovarian cancer. Mol Med Rep 16, 325-330 DOI |
69 | Dejana E (2010) The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 107, 943-952 DOI |
70 | Kim NH, Lee Y and Yook JI (2018) Dishevelling Wnt and Hippo. BMB Rep 51, 425-426 DOI |
71 | Qi H, Sun B, Zhao X et al (2014) Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer. Oncol Rep 32, 771-779 DOI |
72 | Czekierdowski A, Czekierdowska S, Stachowicz N, Lozinski T and Gurynowicz G (2017) Mig-7 expression and vasculogenic mimicry in malignant ovarian tumors. Ginekol Pol 88, 552-561 DOI |
73 | Jo HN, Kang H, Lee A et al (2017) Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. BMB Rep 50, 384-389 DOI |
74 | Carmeliet P and Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 DOI |
75 | Rabbani SA and Mazar AP (2001) The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10, 393-415, x DOI |
76 | Tang J, Wang J, Fan L et al (2016) cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget 7, 24050-24062 DOI |
77 | Hendrix MJ, Seftor EA, Meltzer PS et al (2001) Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 98, 8018-8023 DOI |
78 | Du J, Sun B, Zhao X et al (2014) Hypoxia promotes vasculogenic mimicry formation by inducing epithelialmesenchymal transition in ovarian carcinoma. Gynecol Oncol 133, 575-583 DOI |
79 | Liu W, Lv C, Zhang B, Zhou Q and Cao Z (2017) MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA 23, 1019-1027 DOI |
80 | Lapeyre-Prost A, Terme M, Pernot S et al (2017) Immunomodulatory Activity of VEGF in Cancer. Int Rev Cell Mol Biol 330, 295-342 DOI |
81 | Jeong MS, Bae JS and Jin HK (2019) Vascular endothelial growth factor improves the therapeutic effects of cyclodextrin in Niemann-Pick type C mice. Anim Cells Syst (Seoul) 23, 346-354 DOI |
82 | Mei J, Gao Y, Zhang L et al (2008) VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 30, 29-34 |
83 | Qin L, Ren Y, Chen AM et al (2014) Peroxisome proliferator-activated receptor gamma ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Mol Med Rep 10, 276-282 DOI |